Adcendo
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-b, $135.0M, 2024-11-01attributed |
| Founded | 2021 |
| Headquarters | Copenhagen, Denmark |
| Industry | bio |
| Stage | series-b+ |
| Website | adcendo.com |
Adcendo develops a new generation of antibody-drug conjugates engineered for cancers with high unmet medical need. It targets cancer patients who lack adequate treatment options. Its programs aim to convert ADC science into clinically differentiated medicines with meaningful outcomes.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-11-01 | series-b | $135.0M | undisclosed |
Detected tech stack
LiteSpeed, WordPress 7.0, LiteSpeed Cache, Google Analytics, Google Tag Manager, FitVids.JS 4.27.6, jQuery Migrate 3.4.1, Easy Pie Chart, DoubleClick Floodlight, Cookiebot, Onsen UI, Zepto
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $135.0M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | adcendo.com, read 2026-05-16 |
| Description | self-reported | adcendo.com, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.